Surprisingly, we found that upon vincristine treatment there were no significant changes in the anti-apoptotic proteins MCL-1, BCL-xL, or BCL-2 expression, indicating that cancer cells’ adaptation to this therapy relies on different mechanisms other than increased expression of these proteins (Fig. 3a). Here, BCL2L1 is linked to cancer.